invivodata inc. announced the availability of DiaryPRO® Web, its Web-based electronic PRO (ePRO) data collection solution. An extension of invivodata’s handheld ePRO solution (DiaryPRO® 170 Smartphone), DiaryPRO Web provides all of the scientific design and ease-of-use features necessary for capturing valid, reliable patient data in a Web interface. DiaryPRO Web’s patient interface and electronic assessment capabilities, combined with the ability to run on any personal computer with a Web browser, aims to give the power and flexibility to deliver quality data and increased study efficiencies without deploying devices to allpatients.
“DiaryPRO Web shares many of the same design and service elements that have been used in hundreds of DiaryPRO handheld trials to date, including integration with EPX™, our ePRO management system”, said Doug Engfer, President and CEO of invivodata. “We designed DiaryPRO Web primarily to meet the needs of clinical trial sponsors conducting late stage and post-marketing research, where hundreds or thousands of patients are required to collect the safety or efficacy data necessary for post-approval analysis.”
Because the considerations for using a Web-based ePRO solution are different than those using a handheld ePRO solution, invivodata offers scientific and regulatory support to clinical researchers as they make critical decisions about their ePRO modality options.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.